Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioLineRx (BLRX) Current Leases (2023 - 2025)

Historic Current Leases for BioLineRx (BLRX) over the last 3 years, with Q3 2025 value amounting to $1.0 million.

  • BioLineRx's Current Leases fell 2242.85% to $1.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.0 million, marking a year-over-year decrease of 2242.85%. This contributed to the annual value of $1.1 million for FY2024, which is 1620.16% down from last year.
  • As of Q3 2025, BioLineRx's Current Leases stood at $1.0 million, which was down 2242.85% from $998000.0 recorded in Q2 2025.
  • In the past 5 years, BioLineRx's Current Leases registered a high of $1.7 million during Q1 2023, and its lowest value of $985000.0 during Q1 2025.
  • Its 3-year average for Current Leases is $1.2 million, with a median of $1.3 million in 2023.
  • Data for BioLineRx's Current Leases shows a peak YoY increase of 335.73% (in 2024) and a maximum YoY decrease of 2779.08% (in 2024) over the last 5 years.
  • Over the past 3 years, BioLineRx's Current Leases (Quarter) stood at $1.3 million in 2023, then dropped by 16.2% to $1.1 million in 2024, then fell by 7.22% to $1.0 million in 2025.
  • Its Current Leases stands at $1.0 million for Q3 2025, versus $998000.0 for Q2 2025 and $985000.0 for Q1 2025.